From: Biodegradable collagen matrix implant versus mitomycin-C in trabeculectomy: five-year follow-up
MMC group | OLO group | P | |
---|---|---|---|
Gender (M/F), N° | 11/9 | 12/8 | 1.0a |
Age, yrs. (mean ± SD) | 63.2(7.2) | 65.8(6.4) | 0.234b |
Right/left eyes, N° | 7/13 | 11/9 | 0.340a |
Type of glaucoma (POAG/PEXG), N° | 12/8 | 13/7 | 1.0a |
Preoperative IOP, mmHg (mean ± SD) | 26.7(5.2) | 27.3(6.0) | 0.736b |
Baseline CDVA, decimal notation | 0.8 (±0.33) | 0.75 (±0.31) | 0.624 |
Endpoint CDVA, decimal notation | 0.8 (±0.40) | 0.8 (±0.35) | 1.0 |
Baseline MD, dB (mean ± SD) | -7.80(4.57) | -7.41(5.35) | 0.805b |
Endpoint MD, dB (mean ± SD) | -7.60(4.3) | -7.50(5.6) | 0.949b |
Preoperative medications, N° (mean ± SD) | 2.5(0.3) | 2.6(0.2) | 0.222b |
Duration of preoperative antiglaucoma therapy, yrs. (mean ± SD) | 5.7(1.8) | 6.3(1.4) | 0.246b |
Cataract surgery cases | 3 (15 %) | 2 (10 %) | 1.0 |